Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...
pharmaphorum9d
Vertex and NHS close in on cystic fibrosis drug pricing deal
particularly as the UK has a relatively high incidence of CF, and the second largest disease population in the world. It is two and a half years since Vertex’s Orkambi (lumacaftor+ivacaftor ...
pharmaphorum1d
UK first to approve Vertex, CRISPR drug for blood disorders
Vertex and CRISPR reckon there are around 2,000 patients in the UK eligible for Casgevy. “Both sickle cell disease and beta thalassemia are painful, life-long conditions that in some cases can ...
Sickle cell disease ‘cure’ to be offered to NHS patients
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...
GlobalData on MSN3mon
Vertex shares up after full-year product revenue guidance boost
Vertex added it has also completed regulatory submissions for the vanzacaftor triple therapy in the EU, UK, and Canada, among ...
The Big Issue8d
Big Issue's Changemakers of 2025: Health and disability
Big Issues Changemakers in health and disability are working to improve the lives of those marginalised by society.
Reuters6d
Vertex Pharmaceuticals Inc
UK health system to offer cutting-edge gene therapy for sickle cell disease Future of Healthcategory· January 31, 2025 The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals ...